Zdrowie i gospodarka · 18/03/2014

FDA Releases Draft Guidance on Bioavailability and Bioequivalence Studies for New Drug Applications

The Food and Drug Administration (FDA) has made available a draft guidance document outlining general considerations for bioavailability and bioequivalence studies required for new drug applications and investigational new drug applications, aiming to provide clarity for industry sponsors and applicants.